Gold prices just lower; monthly gains on track
Health Catalyst Inc.’s (NASDAQ:HCAT) Chief Operating Officer, Daniel LeSueur, executed a sale of company shares, as detailed in a recent SEC filing. On February 5, LeSueur sold 5,209 shares of common stock at an average price of $5.7607 per share, totaling approximately $30,007. Following this transaction, LeSueur holds 86,044 shares directly. The sale comes as the stock trades near its 52-week low of $5.32, with shares down about 41% over the past year. According to InvestingPro analysis, the stock currently appears undervalued based on its Fair Value metrics. The sale was conducted under a pre-arranged trading plan established on March 7, 2024, in compliance with Rule 10b5-1. While the company isn’t currently profitable, InvestingPro data shows analysts expect profitability this year, with 4 analysts recently revising earnings estimates upward. Discover more insights about Health Catalyst’s insider trading patterns and financial outlook in the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Health Catalyst Inc. has been the subject of various analyst reports and business developments. The company’s stock target was cut to $10 by Canaccord Genuity, following a series of events including the acquisition of Upfront Healthcare Services (NASDAQ:HCSG), the addition of a new multi-year platform client, and a partnership with Databricks. Similarly, RBC Capital Markets reduced their price target from $9.00 to $7.00, despite optimism about Health Catalyst’s bookings outlook for 2025.
Concurrently, Health Catalyst announced its definitive agreement to acquire Upfront Healthcare Services, Inc., a patient engagement platform provider, expected to be finalized in the first quarter of 2025. The acquisition is part of the company’s strategy to enhance its existing patient engagement portfolio and streamline healthcare services.
In contrast, KeyBanc Capital Markets upgraded Health Catalyst from Sector Weight to Overweight, setting a new price target of $9.00. The firm’s analysis of credit card data indicated sustained healthy utilization levels, which is anticipated to positively influence hospital technology budgets. Additionally, Piper Sandler increased the price target on Health Catalyst’s stock to $12.00, reaffirming an Overweight rating based on the company’s robust year-over-year growth of approximately 50% in adjusted EBITDA for calendar year 2025. These are recent developments in the company’s journey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.